GlassScriptPhysician profile
Thomas T Roesch
NPI 1245206929
$1,361.52
in general payments reported to CMS, 2019-2025
18 companies · $528 in 2025
The $528 reported for 2025 was more than what 81% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.70 · 2022: $20.20 · 2023: $234 · 2024: $563 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $287.10 | 2022-2025 | Imfinzi, Tagrisso, Enhertu |
| Novartis Pharmaceuticals Corporation | $173.85 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $146.99 | 2024-2025 | Keytruda, Lynparza |
| Baxter Healthcare | $85.57 | 2021-2023 | Tisseel, Hillrom - Life 2000 Ventilation System |
| Daiichi Sankyo INC. | $80.60 | 2024-2025 | Enhertu, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $75.66 | 2024-2025 | |
| Genentech USA, INC. | $56.28 | 2023-2025 | Tecentriq, Tecentriq Hybreza |
| Incyte Corporation | $54.41 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Caris Mpi, INC. | $52.11 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $51.23 | 2023-2024 | Krazati |
| Sobi, INC | $49.92 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $49.26 | 2024 | Ultomiris |
| Janssen Biotech, INC. | $47.35 | 2024-2025 | Rybrevant |
| Eisai INC. | $46.27 | 2023-2024 | |
| Celgene Corporation | $43.43 | 2024 | Reblozyl |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $31.65 | 2023 | Signia |
| Solventum Corporation | $15.91 | 2025 | V.A.C.Ulta, Prevena |
| Lilly USA, LLC | $13.93 | 2024 | Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Roesch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.